Internal Medicine, Infectious Disease · Phoenix, AZ
NPI
1770579492
Since 2005
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3330 N 2nd St Ste 401
Phoenix, AZ, 85012
Phone (602) 254-1136
Groups this clinician bills Medicare through
Medicare paid, 2024
$46K
574 services
Medicare patients, 2024
133
Average age 68
Drug cost, 2024
$625K
349 prescriptions
Company payments, 2025
$1,637
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ndidiamaka U Obiesie was code 99232 (hospital e&m - subsequent), 315 times for 89 patients. In total Ndidiamaka U Obiesie billed 574 services in 7 codes, and Medicare paid $46K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-12-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 315 | 89 | $58.54 | $18K |
| 99233 Hospital E&M - Subsequent | Facility | 140 | 73 | $87.99 | $12K |
| 99223 Hospital E&M - Initial | Facility | 109 | 102 | $130.27 | $14K |
By year: 2022 $68K for 813 services; 2023 $55K for 656 services; 2024 $46K for 574 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ndidiamaka U Obiesie prescribed most often to Medicare patients was Dovato (Dolutegravir Sodium/Lamivudine), with 56 prescriptions and refills. In total Ndidiamaka U Obiesie wrote 349 Medicare prescriptions that cost $625K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dovato Dolutegravir Sodium/Lamivudine | 56 | 56 | Under 11 | $170K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 52 | 52 | Under 11 | $210K |
| Cefazolin Sodium Generic | 35 | 35 | Under 11 | $2,131 |
| Teflaro Ceftaroline Fosamil Acetate | 29 | 29 | Under 11 | $105K |
| Cefuroxime Cefuroxime Axetil | 20 | 20 | Under 11 | $1,028 |
| Ertapenem Ertapenem Sodium | 18 | 18 | Under 11 | $4,995 |
| Doxycycline Hyclate Generic | 16 | 16 | Under 11 | $495 |
| Daptomycin Generic | 13 | 13 | Under 11 | $6,529 |
| Fluconazole Generic | 11 | 13 | Under 11 | $874 |
Brand drugs: 162 claims; generic drugs: 187 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ndidiamaka U Obiesie $1,637 ($1,637 in general payments such as food, travel and fees) from 10 companies. The largest payer was ViiV Healthcare Company with $678.
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company GSK | 30 | $678 |
| Gilead Sciences, Inc. GILD | 16 | $432 |
| Shionogi Inc 4507.T | 6 | $200 |
| Melinta Therapeutics, LLC | 4 | $91.92 |
| Astellas Pharma US Inc 4503.T | 2 | $60.57 |
| Insmed, Inc. INSM | 2 | $51.6 |
| Napo Pharmaceuticals Inc | 2 | $46.56 |
| Merck Sharp & Dohme LLC MRK | 2 | $44.09 |
| Theratechnologies Inc. THTX | 1 | $18.3 |
| Janssen Biotech, Inc. JNJ | 1 | $13.65 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.